Novartis Ag · SIX:NOVN
Novartis — Q2 2026 Earnings Presentation
87 slides from Novartis's earnings presentation, Jul 21, 2026
Slide 1: Q2 2026 Results
Content Click below to navigate Investor presentation through the document July 21, 2026 Company overview Financial review Conclusions Appendix References Q2 2026 Results Novartis Q2 Results | July 21, 2026 1
Slide 2: Disclaimer
Content Click below to navigate through the document Disclaimer Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potenti
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References overview Company overview Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q2 Results | July 21, 2026 3
Slide 4: Novartis delivered strong performance across priority brands and launches while advancing the pipeline
Content Click below to navigate through the document Novartis delivered strong performance across priority brands Company overview and launches while advancing the pipeline Financial review Conclusions USD bn, % cc1 Q2 pipeline highlights Appendix Rhapsido® EC and JP approval in CSU; Phase III +1% 0
Slide 5: Growth drivers continued a strong trajectory, up +36% cc in Q2
GROWTH Content Click below to navigate through the document Growth drivers continued a strong trajectory, up +36% cc1 in Q2, Company overview supporting our ability to return to growth Financial review Conclusions Q2 Sales Sales Growth vs. PY Growth vs. PY Appendix USD million USD million cc1 Refere
Slide 6: Kisqali Q2 sales grew +43% cc, outpacing CDK4/6 market
GROWTH Content Click below to navigate through the document Kisqali® Q2 sales grew +43% cc, outpacing CDK4/6 market Company overview Financial review Conclusions Sales evolution US eBC NBRx1 Kisqali Competitor 1 Competitor 2 US: +39% in Q2 reaching 1bn+ Appendix USD m, % cc 80% 70% • Continued mBC l
Slide 7: NATALEE 6-year follow up showed clinically meaningful OS
INNOVATION Content Click below to navigate through the document NATALEE 6-year follow up showed clinically meaningful OS Company overview in broadest at risk eBC population; data to be presented Financial review Conclusions NATALEE Median iDFS follow-up Appendix 28 MONTHS 33 MONTHS 44 MONTHS 55 MONT
Slide 8: Kesimpta Q2 sales grew +32% cc, with increasing TRx share
GROWTH Content Click below to navigate through the document Kesimpta® Q2 sales grew +32% cc, with increasing TRx share Company overview Financial review Conclusions Sales evolution US: +32% in Q2 Appendix USD m, % cc • Increasing TRx share in both B-cell (+2.5%pts1) and MS (+2%pts) markets US Ex-US
Slide 9: Pluvicto Q2 sales grew +43% cc, driven by US pre-taxane mCRPC
GROWTH Content Click below to navigate through the document Pluvicto® Q2 sales grew +43% cc, driven by US pre-taxane mCRPC Company overview and continued ex-US acceleration Financial review Conclusions Sales evolution US: +38% in Q2 Appendix USD m, % cc • Pre-taxane driving >70% new patients • Use a
Slide 10: Leqvio grew +59% cc in Q2 driven by strong demand
GROWTH Content Click below to navigate through the document Leqvio® grew +59% cc in Q2 driven by strong demand Company overview Financial review Conclusions Sales evolution US: +55% in Q2, outgrowing advanced lipid-lowering market1,2,3,4 Appendix USD m, % cc • MOTRx +49% (market +37%) demonstrating
Slide 11: Scemblix Q2 sales grew +89% cc driven by both US and ex-US
GROWTH Content Click below to navigate through the document Scemblix® Q2 sales grew +89% cc driven by both US and ex-US Company overview Financial review Conclusions Sales evolution US 1L NBRx Share (R3M)1 US: +93% in Q2 Appendix USD m, % cc Competitor 1 Scemblix Competitor 2 Competitor 3 Competitor
Slide 12: Cosentyx Q2 sales grew +10% cc mainly driven by strong US growth
GROWTH Content Click below to navigate through the document Cosentyx® Q2 sales grew +10% cc mainly driven by strong US growth Company overview Financial review Conclusions Sales evolution US HS Naive NBRx Share (R4W)1 US: +16% in Q2 Appendix USD m, % cc Competitor 1 (molecule1) Competitor 2 Cosentyx
Slide 13: Rhapsido with strong CSU launch trajectory and Phase III CIndU data
GROWTH Content Click below to navigate through the document Rhapsido® with strong CSU launch trajectory and Phase III CIndU data Company overview supporting broader urticaria potential Financial review Conclusions CSU launch CIndU Appendix Continued • >4k prescribers1 with ~53% allergists and ~47% d
Slide 14: Ianalumab showed favorable ESSDAI benefit in longer term follow up
INNOVATION Content Click below to navigate through the document Ianalumab showed favorable ESSDAI benefit in longer term follow up; Company overview US launch in Sjögren’s disease expected H2 Financial review Conclusions Pooled NEPTUNUS data1 NEPTUNUS 1 & 2 Week 48 additional Appendix 0 analyses1 •
Slide 15: Del-zota BLA submitted and del-brax FSHD biomarker cohort data positive
INNOVATION Content Click below to navigate through the document Del-zota BLA submitted and del-brax FSHD biomarker cohort data positive Company overview Financial review Conclusions Del-zota: First FDA submission Del-brax: Phase I/II study met primary and key secondary Appendix for the therapeutic u
Slide 16: Remain focused on significant H2 pipeline readouts
INNOVATION Content Click below to navigate through the document Remain focused on significant H2 pipeline readouts Company overview Financial review Conclusions Select readouts CRM Immunology Neuroscience Oncology Appendix References H1 H2 Rhapsido® CIndU Pelacarsen CVRR-Lp(a) Rhapsido HS PhIII PhII
Slide 17: Financial review and 2026 guidance
Content Click below to navigate through the document Company overview Financial Financial review Conclusions reviewFinancial and review Appendix References 2026 guidance and 2026 guidance Mukul Mehta Chief Financial Officer Mukul Mehta Chief Financial Officer Novartis Q2 Results | July 21, 2026 17
Slide 18: Q2 net sales grew +1% cc with core operating income flat
FINANCIAL PROFILE Content Click below to navigate through the document Q2 net sales grew +1% cc with core1 operating income flat, as growth Company overview drivers and continued productivity offset generic erosion Financial review Conclusions Key figures1 Change vs. PY Change vs. PY Q2 Q2 H1 H1 App
Slide 19: Continuing our shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate through the document Continuing our shareholder-friendly capital allocation strategy Company overview Financial review Conclusions Appendix Investing in the business Returning capital to shareholders References Investments in organic business Consist
Slide 20: Reaffirming 2026 full year guidance
FINANCIAL PROFILE Content Click below to navigate through the document Reaffirming 2026 full year guidance Company overview Financial review Conclusions Expected, barring unforeseen events; growth vs. PY in cc1 Appendix Net expected to grow Core1 operating expected to decline sales income References
Slide 21: H1 delivered sales at upper end of guidance
FINANCIAL PROFILE Content Click below to navigate through the document H1 delivered sales at upper end of guidance; H2 with accelerating quarterly Company overview growth Financial review Conclusions 2026 growth vs. PY (cc)1 Appendix Illustrative References 1. Constant currencies (cc) and core resul
Slide 22: Expected currency impact for 2026
FINANCIAL PROFILE Content Click below to navigate through the document Expected currency impact for 2026 Company overview Financial review Conclusions Currency impact vs. PY Appendix %pts, assuming mid-July exchange rates prevail in 2026 References Actual Simulation 1. Core results are non-IFRS meas
Slide 23: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q2 Results | July 21, 2026 23
Slide 24: Delivered H1 topline performance at the upper end of guidance
Content Click below to navigate through the document Company overview Financial review Delivered H1 topline performance at the Remain on track Conclusions upper end of guidance, with Q2 returning to to deliver our FY guidance sales growth Appendix References Progressing first indications Focused on
Slide 25: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Appendix Financial performance Innovation: Clinical trials Appendix Abbreviations References Novartis Q2 Results | July 21, 2026 25
Slide 26: Key innovation milestones in 2026
INNOVATION Content Click below to navigate through the document Key innovation milestones in 2026 Company overview 2026 selected key events (expected) H1 2026 H2 2026 Status as of end Q2 Financial review Rhapsido® CIndU3 US Regulatory Pluvicto® mHSPC US, JP, CN Conclusions decisions Rhapsido® CSU EU
Slide 27: Our pipeline projects at a glance
INNOVATION Content Click below to navigate through the document Our pipeline projects at a glance Company overview Financial review Conclusions Phase I/II Phase III Registration Total Appendix Innovation: Pipeline overview Oncology 19 11 1 31 Financial performance Innovation: Clinical trials Solid t
Slide 28: Novartis pipeline in Phase I
INNOVATION Content Click below to navigate Novartis pipeline in Phase I 18 lead indications through the document Lead indication Oncology Neuroscience Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) EDK060 EDK060 - Charcot-Marie-Tooth disease Financial review Sol
Slide 29: Novartis pipeline in Phase II
INNOVATION Content Click below to navigate Novartis pipeline in Phase II 23 lead indications through the document Lead indication Oncology Immunology Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) GHZ339 GHZ339 - Atopic dermatitis Financial review Solid tumors G
Slide 30: Novartis pipeline in Phase III
INNOVATION Content Click below to navigate Novartis pipeline in Phase III 10 lead indications through the document Lead indication Oncology Neuroscience Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis,
Slide 31: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration 1 lead indications through the document Lead indication Oncology Company overview Code Name Mechanism Indication(s) Financial review Solid tumors AAA617 Pluvicto® Radioligand therapy target PSMA Metastatic hormone sensitive
Slide 32: Novartis submission schedule
INNOVATION Content Click below to navigate through the document Novartis submission schedule New Molecular Entities: Lead and supplementary indications Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2026 2027 2028 ≥2029 Conclusions del-zota del-desiran 225
Slide 33: Existing brands submission schedule
INNOVATION Content Click below to navigate through the document Novartis submission schedule Supplementary indications for existing brands Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2026 2027 2028 ≥2029 Conclusions Cosentyx® Fabhalta® Lutathera® Fabhal
Slide 34: Net debt increased by USD 17.5bn
Content Click below to navigate through the document Net debt1 increased by USD 17.5bn as the FCF was more than offset mainly Company overview by M&A and the annual dividend payment Financial review Conclusions USDbn -17.5 Appendix Innovation: Pipeline overview Financial performance Innovation: Clin
Slide 35: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview IR Clinical Studies Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience
Slide 36: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Cardiovascular, Conclusions Appendix Cardiovascular, Innovation: Pipeline overview RenalRenal andandMetabolic Financial performance Innovation: Clinical trials Metabolic > C ardiovascular, Renal and Metabolic > I
Slide 37: abelacimab – FXI/FXIa inhibitor
Content abelacimab – FXI/FXIa inhibitor Click below to navigate through the document Company overview NCT05712200 LILAC (CMAA868A2302) Financial review Indication Atrial fibrillation (AF) Phase Phase 3 Conclusions Patients 1900 Primary Efficacy: Time to first event of ischemic stroke or systemic emb
Slide 38: atrasentan - ETA receptor antagonist
Content atrasentan - ETA receptor antagonist Click below to navigate through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 404 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 39: Fabhalta® - CFB inhibitor
Content Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor Click below to navigate through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 40: Leqvio® - siRNA (regulation of LDL-C)
Content Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 41: Leqvio® - siRNA (regulation of LDL-C)
Content Leqvio® - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) Financial review Indication CVRR (Primary prevention) Phase Phase 3 Conclusions Patients 14111 Primary Time to the first occurrence of 4P-MACE Appendix
Slide 42: LTP001 - SMURF1 Inhibitor
Content LTP001 - SMURF1 Inhibitor Click below to navigate through the document Company overview NCT06649110 (CLTP001A12202) Financial review Indication Pulmonary arterial hypertension Phase Phase 2 Conclusions Patients 232 Primary Part A- Number of participants with Adverse events (AEs) and Serious
Slide 43: PAC001 – anti-IL6 mAb
Content PAC001 – anti-IL6 mAb Click below to navigate through the document Company overview NCT06362759 TRANQUILITY (CPAC001A12201) Financial review Indication ASCVD Phase Phase 2 Conclusions Patients 143 Primary Evaluate the effects of TOUR006 compared with placebo on hs-CRP Appendix Outcome Innova
Slide 44: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content pelacarsen - Antisense oligonucleotide (ASO) Click below to navigate targeting Lp(a) through the document Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 45: QCZ484
Content QCZ484 Click below to navigate through the document Company overview NCT06857955 (CQCZ484A12201) Financial review Indication Hypertension Phase Phase 2 Conclusions Patients 380 Primary Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by Appendix Outcome ambulatory b
Slide 46: zigakibart - Anti-APRIL
Content zigakibart - Anti-APRIL Click below to navigate through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 383 Primary Change from Baseline to week 104 in eGFR Appendix Outcome Innovation: Pipeline o
Slide 47: DII235
Content DII235 Click below to navigate through the document Company overview NCT07235046 (CDII235A12201) Financial review Indication Risk reduction in cardiovascular disease w elevated Lp(a) Phase Phase 2b Conclusions Patients 200 Primary 1) Time averaged percentage change from baseline in Lp(a) mea
Slide 48: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Immunology Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-mar
Slide 49: GHZ339
Content GHZ339 Click below to navigate through the document Company overview NCT06947993 PLATFORM-AD (CADPT17A12201) Financial review Indication Atopic dermatitis Phase Phase 2 Conclusions Patients 224 Primary Outcome Change from baseline in the Eczema Area and Severity Index (EASI) score at Appendi
Slide 50: GIA632 – IL-15 mAb
Content GIA632 – IL-15 mAb Click below to navigate through the document Company overview NCT07431177 (CGIA632B12201) NCT07220577 (CGIA632A12201) Financial review Indication Non-segmental Vitiligo Indication Atopic dermatitis Phase Phase 2 Phase Phase 2 Conclusions Patients 210 Patients 84 Primary Pe
Slide 51: ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell depletor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 420 Primary Outcome Frequency and percentage of parti
Slide 52: ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell depletor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor depletor through the document Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 53: ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell depletor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT06470048 VENUSS (CVAY736S12201) Financial review Indication Systemic sclerosis Phase Phase 2 Conclusions Patients 200 Primary 3/5 Revised Composite Response Index in S
Slide 54: ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell depletor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT07621809 THALASSA (CVAY736A22301) Financial review Indication Sjögren´s Disease (high symptom burden) Phase Phase 3 Conclusions Patients 570 Primary Change in baseline
Slide 55: Rhapsido® - BTK inhibitor
Content Rhapsido® - BTK inhibitor Click below to navigate through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Score;
Slide 56: Rhapsido® - BTK inhibitor
Content Rhapsido® - BTK inhibitor Click below to navigate through the document Company overview NCT06799000 RECHARGE1 (CLOU064J12301) NCT06840392 RECHARGE2 (CLOU064J12302) Financial review Indication Hidradenitis suppurativa Indication Hidradenitis suppurativa Phase Phase 3 Phase Phase 3 Conclusions
Slide 57: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Neuroscience Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n
Slide 58: Del-desiran – siRNA DMPK knockdown
Content Del-desiran – siRNA DMPK knockdown Click below to navigate through the document Company overview NCT06411288 HARBOR (CEWF980A12301) Financial review Indication Myotonic Dystrophy Type 1 (DM1) Phase Phase 3 Conclusions Patients 159 Primary Hand function – video Hand Opening Time (vHOT) Append
Slide 59: Del-brax – siRNA DUX4 knockdown
Content Del-brax – siRNA DUX4 knockdown Click below to navigate through the document Company overview NCT07038200 FORTITUDE-3 (CDWH213A12301) Financial review Indication Facioscapulohumeral Muscular Dystrophy (FSHD) Phase Phase 3 Conclusions Patients 200 Primary Quantitative Muscle Testing (QMT) com
Slide 60: Del-zota – PMO mediated exon skipping
Content Del-zota – PMO mediated exon 44 skipping Click below to navigate through the document Company overview NCT06244082 EXPLORE44OLE (CKPE179A12201) Financial review Indication Duchenne Muscular Dystrophy (DMD) Phase Phase 2 Conclusions Patients 39 Primary Incidence of Treatment Emergent Adverse
Slide 61: Fabhalta® - CFB inhibitor
Content Fabhalta® - CFB inhibitor Click below to navigate through the document Company overview NCT123456 APPRAISE (CLNP023Q12301) Financial review Indication Generalized Myasthenia Gravis (gMG) Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 in Myasthenia Gravis Activ
Slide 62: Kesimpta® - anti-CD20
Content Kesimpta® - anti-CD20 Click below to navigate through the document Company overview NCT06869785 FILIOS (COMB157Q12301) Financial review Indication Multiple Sclerosis new dosing regimen Phase Phase 3 Conclusions Patients 180 Primary Ofatumumab plasma pharmacokinetics - area under the curve, u
Slide 63: Mayzent® – S1P1,5 receptor modulator / Kesimpta – CD20 antagonist
Content Mayzent® – S1P1,5 receptor modulator / Kesimpta – CD20 antagonist Click below to navigate through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple Sclerosis, pediatrics Phase Phase 3 Conclusions Patients 129 Primary Annualized relapse rate (A
Slide 64: NIO752 – Tau antisense oligonucleotide
Content NIO752 – Tau antisense oligonucleotide Click below to navigate through the document Company overview NCT07498426 PRESERVE (CNIO752A12301) Financial review Indication Progressive Supranuclear Palsy Phase Phase 3 Conclusions Patients 300 Primary Change from baseline in the mPSPRS-10 score Appe
Slide 65: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple Sclerosis, relapsing Indication Multiple Sclerosis, relapsi
Slide 66: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT06744920 RELIEVE (CLOU064O12301) Financial review Indication Myasthenia Gravis (MG) Phase Phase 3 Conclusions Patients 180 Primary Change from baseline to Month 6 in Myasthenia Gravis Activity of Da
Slide 67: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT07225504 REMASTER (CLOU064P12301) Financial review Indication Secondary progressive multiple sclerosis Phase Phase 3 Conclusions Patients 1275 Primary Time to 6-month confirmed disability progressio
Slide 68: VHB937 - TREM2 stabilizer and activator
Content VHB937 - TREM2 stabilizer and activator Click below to navigate through the document Company overview NCT0664381 ASTRALS (CVHB937B12201) NCT07094516 (CVHB937A12201) Financial review Indication Amyotrophic Lateral Sclerosis (ALS) Indication Alzheimer's Disease (AD) Phase Phase 2 Phase Phase 2
Slide 69: Votoplam – Huntington modulator
Content Votoplam – Huntington modulator Click below to navigate through the document Company overview NCT07326709 INVEST-HD (CHTT227A12301) Financial review Indication Huntington’s Disease (HD) Phase Phase 3 Conclusions Patients 770 Primary Change from Baseline in cUHDRS score Appendix Outcome Innov
Slide 70: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Oncology Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-market
Slide 71: 225Ac-PSMA-617 - Radioligand therapy target PSMA
Content 225Ac-PSMA-617 - Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT06855277 AcTFirst (CAAA817B12301) NCT06780670 PSMAcTION (CAAA817A12201) Financial review Indication Metastatic castration-resistant prostate cancer Indication post Lu Metastatic
Slide 72: ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell depletor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05653349 VAYHIT1 (CVAY736I12301) Financial review Indication 1L Immune Thrombocytopenia Phase Phase 3 Conclusions Patients 225 Primary Rate of Stable Response off trea
Slide 73: ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell depletor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 74: iptacopan - CFB inhibitor
Content iptacopan - CFB inhibitor Click below to navigate through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) NCT05935215 APPRECIATE (CLNP023F12302) Financial review Indication Atypical haemolytic uraemic syndrome Indication Atypical haemolytic uraemic syndrome Phase Phase 3 P
Slide 75: Lutathera® - Radioligand therapy target SSTR
Content Lutathera® - Radioligand therapy target SSTR Click below to navigate through the document Company overview NCT06784752 NETTER-3 (CAAA601A62301) Financial review Indication Gastroenteropancreatic neuroendocrine tumors Phase Phase 3 Conclusions Patients 240 Primary Progression Free Survival (P
Slide 76: Pelabresib – BET Inhibitor
Content Pelabresib – BET Inhibitor Click below to navigate through the document Company overview NCT04603495 MANIFEST-2 (CDAK539A12301) NCT07357727 MANIFEST-3 (CDAK539A12303) Financial review Indication Myelofibrosis Indication Myelofibrosis Phase Phase 3 Phase Phase 3 Conclusions Patients 430 Patie
Slide 77: Pluvicto® - Radioligand therapy target PSMA
Content Pluvicto® - Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT05939414 PSMA-DC (CAAA617D12302) Financial review Indication Oligometastatic prostate cancer Phase Phase 3 Conclusions Patients 450 Primary Metastasis Free Survival (MFS) Appendix Out
Slide 78: luxdegalutamide - Androgen receptor protein degrader
Content luxdegalutamide - Androgen receptor protein degrader Click below to navigate through the document Company overview NCT07047118 (CJSB462B12201) NCT06991556 (CJSB462C12201) Financial review Indication Metastatic castration resistant prostate cancer Indication Metastatic hormonal sensitive pros
Slide 79: Vijoice® - PI3Ki
Content Vijoice® - PI3Ki Click below to navigate through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and pediatri
Slide 80: In-market Brands & Global
Content Click below to navigate through the document Company overview Financial review In-market Brands Conclusions Appendix In-market Brands Innovation: Pipeline overview & Global Health Financial performance Innovation: Clinical trials & Global Health > C ardiovascular, Renal and Metabolic > I mmu
Slide 81: Ganaplacide+lumefantrine - Non-artemisinin plasmodium falciparum inhibitor
Content Ganaplacide+lumefantrine - Non-artemisinin Click below to navigate plasmodium falciparum inhibitor through the document Company overview NCT05842954 KALUMA (CKLU156A12301) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1720 Primary PCR-corrected adequat
Slide 82: Rydapt® - Multi-targeted kinase inhibitor
Content Rydapt® - Multi-targeted kinase inhibitor Click below to navigate through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 83: EDI048
Content EDI048 Click below to navigate through the document Company overview NCT07249463 (CEDI048A12201) Financial review Indication Cryptosporidiosis infection Phase Phase 2 Conclusions Patients 80 Primary Average stool grade after the initiation of EDI048 or placebo treatment Appendix Outcome Inno
Slide 84: Abbreviations
Content Click below to navigate through the document Abbreviations Company overview Financial review Abbreviation Full form Abbreviation Full form Abbreviation Full form 1L First-line ET Endocrine Therapy N0/N1 Node-negative / Node-positive Conclusions 2L Second-line EULAR European Alliance of Assoc
Slide 85: References (1/3)
Content Click below to navigate through the document References (1/3) Company overview Financial review Conclusions Kisqali® (slide 6 references) 1 IQVIA Market Sizing Monthly Report, May 2026, rolling 3 months; Data lag ~ 2 months. 2 eBC DE & UK NBRx monthly share from BEST as of Apr 2026. Appendix
Slide 86: References (2/3)
Content Click below to navigate through the document References (2/3) Company overview Financial review Conclusions Scemblix® (slide 11 references) 1 US IQVIA CML market sizing report, Jun 2026 (Mar 2026 data month); Nomenclature changed to more accurately reflect the IQVIA patient-level data used i
Slide 87: References (3/3)
Content Click below to navigate through the document References (3/3) Company overview Financial review Conclusions Ianalumab (slide 14 references) 1 Mariette X, Grader-Beck T, Finzel S, et al. Efficacy and safety of the ianalumab global Phase III studies (NEPTUNUS-1 and NEPTUNUS-2) and their extens